2 completed, 1 recruiting, 1 unknown. 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Fosaprepitant 150 mg: new trials by email Literature Review of Fosaprepitant 150 mg trials Research Report on Fosaprepitant 150 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea | Phase 2 / Phase 3 | Recruiting | Montefiore Medical Center | 200 | 2024-11-13 | 2026-05-18 |
| Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery Ondansetron 8mg, Fosaprepitant 150 mg - Postoperative Nausea and Vomiting, Anesthesia Complication | Not applicable | Unknown | Qilu Hospital of Shandong University | 234 | 2023-06-01 | 2023-06-06 |
| Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia Fosaprepitant 150 mg - Postoperative Nausea | Phase 4 | Completed | Stanford University | 11 | 2018-01-01 | 2022-07-18 |
| Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) Fosaprepitant 150 mg, Aprepitant 165 mg, Aprepitant 250 mg - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2010-04-01 | 2015-02-25 |
Postoperative Nausea and Vomiting (2) · Vomiting (2) · Nausea (1) · Thoracic Diseases (1)
Merck Sharp & Dohme LLC (1) · Montefiore Medical Center (1) · Qilu Hospital of Shandong University (1) · Stanford University (1)
United States (2)
Benjamin W Friedman, MD MS (1) · Mark A Burbridge, MD (1)